- Tonix Pharmaceuticals (TNXP +8.3%) continues a big run after SA Pro's Joe Springer argues its TNX-102 SL drug for treatment of fibromyalgia and Post Traumatic Stress Disorder makes the stock one of the most undervalued in the market and a potential multi-bagger.
- Management's "Celgene Contingency" attitude might prevent a quick takeover by a potential marketing partner, but that may be to the long-term benefit of shareholders, says Springer, reminding Celgene also fended away offers and a decade later is a $60B company.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs